| Biological Information | |
|---|---|
| Background Information: | CAL-101 (Idelalisib, GS-1101, Zydelig) is a synthetic drug that potently inhibits the phosphoinositide 3-kinase P110δ(PI3Kδ) (IC50=2.5nM), with 40-300-fold selectivity over p110α, β, and γ. CAL-101 is FDA approved for treatment of chronic lymphocytic leukemia (CLL) in combination with rituximab. Provided as 10 mg of dry powder. |
| Target Name: | Idelalisib |
| Usage | |
| Product Type: | Control Ligands & Inhibitors |
| Application: | Drug Discovery & Development |
| Storage Conditions: | Store at -20°C. Please avoid multiple freeze/thaw cycles. |
| Usage Disclaimer: | These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information. |
| Additional Information | |
| Brand: | DiscoverX |
CAL-101 (Idelalisib, GS-1101)
CAL-101 (Idelalisib, GS-1101) is an inhibitor for PI3Kδ/P110δ. This product is provided as 10 mg of dry powder.
Datasheets
92-1258 Datasheet
View Document